Aripiprazole Tablet
Product Images NDC 70518-2584

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2584). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 2mg 70518 2584 01

Aripiprazole 2 mg tablet packaging label showing quantity of 180 tablets. The label includes NDC number 70518-2584-01 and indicates the product is repackaged by RemedyRepack Inc. Directions note to see package insert. The label also includes storage temperature guidelines and a QR code, with the manufacturer listed as Torrent, Bharuch, India.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 2 mg oral tablets label showing quantity of 30 tablets. The label displays the proprietary name aripiprazole, dosage strength, and quantity. It includes manufacturer details as MFG: Torrent, Bharuch, India, with repackaging by RemedyRepack Inc., Indiana, PA. The label also provides storage directions and a QR code.*

FDA Label Image

Image Fig1 Effectofotherdrug Arip

A pharmacokinetic chart depicting the effects of various drugs on aripiprazole plasma exposure, showing fold changes and 90% confidence intervals for AUC and Cmax relative to reference without interacting drug. It includes inhibitors (ketoconazole, quinidine), inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis represents change relative to reference (0.5 to 3.0 fold).*

FDA Label Image

Image Fig2 Effectofotherdrug Dehydroarip

A pharmacokinetic figure titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing the fold change and 90% confidence intervals of dehydro-aripiprazole concentrations with co-administration of various drugs. The chart plots fold change relative to a reference without interacting drugs on the x-axis, with listed drugs including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others such as valproate, lithium, and lorazepam. AUC and Cmax parameters are depicted for each drug interaction.*

FDA Label Image

Image Fig3 Effectofarip Otherdrug

A forest plot graph depicting the effects of aripiprazole on the pharmacokinetics of various other drugs. The chart shows fold changes and 90% confidence intervals for multiple drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0.*

FDA Label Image

Image Fig4 Effectofintrinsicfactor Arip

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing a chart of aripiprazole fold change with 90% confidence intervals across various intrinsic factors: CYP2D6 metabolizer status, gender, age groups, degrees of hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference, ranging from 0.5 to 3.0, with data points plotted for AUC and Cmax comparisons.*

FDA Label Image

Image Fig5 Effectofintrinsicfactor Dehydroarip

A pharmacokinetic effect chart illustrating the fold change and 90% confidence interval for dehydro-aripiprazole relative to various intrinsic factors. The factors include CYP2D6 metabolizer status, gender, age groups, degrees of hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference values, and the y-axis lists pharmacokinetic parameters AUC and Cmax for each factor comparison.*

FDA Label Image

Image Fig6 Schizophreniastudy 5

Kaplan-Meier plot showing the cumulative proportion of patients with relapse over time in a schizophrenia study, comparing aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Number of subjects at risk is listed below the x-axis for both groups.*

FDA Label Image

Image Fig7 Bipolarstudy 7

Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse over days from randomization in a Bipolar Study. The graph compares aripiprazole (solid blue line) and placebo (dashed red line) groups, with the y-axis representing the proportion with relapse and number of subjects at risk displayed below the x-axis at various time points.*

FDA Label Image

Image Fig8 Bipolarstudy 8

A Kaplan-Meier curve chart titled 'Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse to Any Mood Event (Bipolar Study 8)' showing the proportion with relapse on the y-axis and days from randomization on the x-axis. Two lines compare ABILIFY (blue solid) and PLACEBO (red dashed) groups over 364 days, with a table of number of subjects at risk below the x-axis.*

FDA Label Image

Image Fig9 Tourettesdisorderstudy1

A line graph titled "Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette's Disorder Study 1)," showing change in YGTSS total tic score over 8 weeks of treatment. The graph compares three groups: ARIP-LOW, ARIP-HIGH, and placebo, with the vertical axis representing least square mean change in YGTSS total tic score from baseline and the horizontal axis representing weeks of treatment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.